Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2020/05/025343
CTRI/2020/05/025343Not yet recruitingPhase 2

Integration of Ayurvedic proprietary formulation (SUVED) and Whole Colostrum (REIMMUGEN) intervention given together, to reduce morbidity and mortality in suspected and confirmed COVID patients admitted to COVID ward in Pune. - SU-REM-COVID

Health Solutions0 sites0 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •Patients admitted to COVID ward; symptomatic or non-symptomatic.
  • •Patients under observation in COVID quarantine.

Exclusion Criteria

  • •Below age 18, pregnant and lactating women; Patients in COVID ICU with ventilator support.

Investigators

Sponsor
Health Solutions

Similar Trials

Completed
Phase 3
Impact of effect of Ayurvedic treatment Divya Phyter on Functional Constipation.
CTRI/2023/02/049649Patanjali Research Institute governed by Patanjali Research Foundation Trust, Haridwar Uttarakhand207
Completed
Phase 2
Role of Triphaladi mouthwash in patients of dental caries.
CTRI/2018/02/012165IPGT and RA40
Completed
Phase 2
Ayurvedic treatment of Allergic Rhinitis
CTRI/2017/12/010937CCRAS107
Recruiting
Phase 3
Effect of ayurvedic drug Divya Trighan in patients with increased uric acid.
CTRI/2023/07/055433Patanjali Research Institute governed by Patanjali Research Foundation Trust
Recruiting
Phase 3
To evaluate the efficacy of traditional Ayurvedic formulation (Divya Melanogrit) in Leukoderma.
CTRI/2023/02/049953Patanjali Research Institute governed by Patanjali Research Foundation Trust